Project Grant R01CA301372
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$605K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award of $187,000 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research at Northwestern University to investigate the role of lipid metabolism in epigenetic reprogramming and its potential impact on estrogen receptor-negative breast cancer development. The key objectives are to: 1) explore whether octanoic acid-mediated increases in neural gene expression also manifest at the protein level; 2) determine which histone...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) totaling $180,632.00 to the University of Pittsburgh to study methods for inhibiting breast cancer metastasis. The key objectives of this initiative are to: Discover and validate compounds that can effectively block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this engulfment process has been linked to increased tumor aggressiveness and metastatic potential. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $444,569 over a 2-year period from June 1, 2024 to May 31, 2026 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop more representative patient-derived models of hormone receptor positive (HR+) breast cancer, including those from underrepresented ethnicities. The award aims to expand the availability of these models and investigate therapeutic...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will fund research at the University of Toledo Health Science Campus to investigate the molecular basis and targeting of fatty acid synthase (FASN) in order to enhance the utility of PARP inhibitors for treating triple-negative breast cancer (TNBC). The $524,419 award, running from February 1, 2025 to January 31, 2030, will support three specific aims: 1)...
The National Cancer Institute (NCI) awarded a $3,537,456 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Regents of the University of California, San Francisco (UCSF) to support a comprehensive research program to advance the science and evaluation of subtype-specific risk-based breast cancer screening and prevention. The key products and services delivered through this award include: Extending enrollment of the WISDOM study to 45,000 women in the U.S....
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is for a project titled "Engineered Biomimetic Collective Cancer Invasion Models for Screening Chemotherapeutic Agents." The $443,191 award, with a project period running from June 2024 to May 2029, aims to develop innovative in vitro tumor invasion models using engineered biomimetic substrates and 3D tissue-engineered constructs. These models will...
This federal Project Grant award of $684,333 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to evaluate whether patient and provider decision support that compares breast cancer and cardiovascular disease risk can improve the acceptance and uptake of chemoprevention among racially/ethnically diverse women at high risk for breast cancer. The key products and services to be delivered under this 5-year grant, which begins on...
This federal Project Grant award for $781,436 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to optimize anti-NMDAR antibodies for the treatment of triple-negative breast cancer (TNBC). Specifically, the award aims to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen candidate anti-NMDAR antibodies using cryo-EM to identify structural changes that drive neurological toxicity, and 3) evaluate the therapeutic...
This federal Project Grant award for $456,048.00, granted by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at Cold Spring Harbor Laboratory on the mechanisms by which breast cancer disrupts normal circadian rhythms in glucocorticoid hormones. The key objectives are to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs in response to breast cancer, identify the underlying...
This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...